Dr Blake is a Radiologist and Nuclear  Physician and brings a wealth of technical and industry experience to Resonance Health. He has been a partner of Perth Radiological Clinic since 1997 and is currently the Chairman of the company. Dr Blake, additionally held the position of Head of Department of Nuclear Medicine at Royal Perth Hospital for a numbers of years. He has published more than a dozen peer review research papers and has been contributing author to the Royal Australian and New Zealand College of Radiologists (RANZCR) Imaging Guidelines. Dr Blake has additionally held positions as Secretary and Treasurer of the WA Branch of the RANZCR. Dr Blake has an MBA from Melbourne University, is a Graduate of the Australian Institute of Company Directors and holds directorships on a number of company boards.

Ms Dunne joined Resonance Health in October 2003 and has been actively involved in all aspects of the business including business development and commercialisation of FerriScan, developing alliances with pharmaceutical industry partners and obtaining regulatory approval in various countries.
Ms Dunne has a wealth of experience in senior positions across industry. She worked for IBM for eleven years in financial, marketing and management positions and spent five years with KPMG Consulting as a Senior Manager working across a broad spectrum of industry and project areas that focused on improved business processes and implementation of new technology.
Ms Dunne holds a Business Degree, a Graduate Diploma in Applied Finance and is a Graduate of the Australian Institute of Company Directors.

Dr St Pierre is widely published in the field of iron in medicine and biology and built a reputation as a physicist with an outstanding understanding of the fundamental properties of the iron deposits that occur in iron overload diseases. Dr St Pierre who is a Professor led the team which developed the FerriScan technology at The University of Western Australia.

Stewart has over 20 years of senior executive and Board experience in commercial technology companies in the medical, food, agricultural and industrial sectors. He was a founder of Biopacific Ventures, a $120m New Zealand based fund. He is currently a Venture Partner with the Swiss Inventages Fund, a €1.5 billion life science fund, funded by Nestle.
Stewart was the founding CEO of Phylogica Ltd (ASX:PYC) a company with a peptide drug discovery technology. Before this, he was CEO of Celentis and managed the commercialisation of intellectual property from AgResearch in New Zealand with 650 Scientists and $130m revenues.
Stewart is an Investment Director with IB Managers who have Australian and European life-science funds. Stewart is the Chairman of Hatchtech Pty Ltd who have a novel anti pest egg hatching technology and are in clinical trials with a headlice treatment. Stewart is a Director of Healthlinx (ASX:HTX) who have developed the first successful diagnostic for Ovarian Cancer and Genesis R&D (ASX:GEN) who have developed new ways to deliver siRNA drugs. Stewart sits on the Senate at Murdoch University, and the Federal Government Advisory Panel for Industrial Biotechnology and the Board of AusBiotech Ltd, the industry body for biotechnology.